Zijlstra J G, de Jong S, de Vries E G, Mulder N H
Department of Internal Medicine, University Hospital Groningen, The Netherlands.
Med Oncol Tumor Pharmacother. 1990;7(1):11-8. doi: 10.1007/BF03000485.
The enzymes involved in the regulation of the three-dimensional structure of DNA, topoisomerase I and II, are important for the handling of DNA during vital cellular processes such as translation, transcription and mitosis. The enzymes are currently being studied intensively, they are being biochemically characterized and their mechanism of action is now better understood. Empirically discovered antitumor drugs appear to interfere with these enzymes, especially topoisomerase II. The DNA-topoisomerase II complex, which is an intermediate in the normal enzyme pathway, is stabilized by the drug and forms a 'cleavable complex', which appears to be cytotoxic. The drugs involved are, e.g. anthracyclines, epipodophyllotoxins and acridines. The central role of this enzyme offers the cell an opportunity for the development of resistance by down-regulation of this enzyme or the production of resistant mutants, provided the adaptation does not hamper other vital cell functions. Knowledge of the working mechanism and the cellular regulation of the topoisomerases might lead to the selection of most effective drugs and treatment schedules, and to circumvention of drug resistance.
参与DNA三维结构调控的酶,拓扑异构酶I和II,在诸如翻译、转录和有丝分裂等重要细胞过程中对DNA的处理至关重要。目前正在对这些酶进行深入研究,对它们进行生物化学特性分析,并且现在对其作用机制有了更好的理解。通过经验发现的抗肿瘤药物似乎会干扰这些酶,尤其是拓扑异构酶II。DNA-拓扑异构酶II复合物是正常酶途径中的一个中间体,会被药物稳定并形成一种“可裂解复合物”,这种复合物似乎具有细胞毒性。所涉及的药物例如有蒽环类、表鬼臼毒素和吖啶类。这种酶的核心作用为细胞提供了通过下调该酶或产生抗性突变体来产生耐药性的机会,前提是这种适应性变化不会妨碍其他重要的细胞功能。了解拓扑异构酶的作用机制和细胞调控可能会有助于选择最有效的药物和治疗方案,并规避耐药性。